EUVIMEDEUVIMED entdecken
FallberichtKohortenstudieOpen Access · CC BY-NC-ND 4.0

SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Moderate-to-Severe Psoriasis Receiving Biologic Therapy: A Propensity Score-Matched Cohort Study

A Gotor-Rivera, J Hernández Sánchez, E Chamorro Jiménez, E García Rivera, P L Ortiz Romero, R Rivera-Diaz

Actas Dermo-Sifiliográficas · 2027-02 · 118 (2) · 104756

DOI: 10.1016/j.ad.2026.104756 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Actas Dermo-Sifiliográficas, 2027-02. Verfasst von A Gotor-Rivera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario "12 de Octubre", Madrid, Spain. Electronic address: alfonso.gotor@salud.madrid.org. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with moderate-to-severe psoriasis have an increased risk of cardiovascular disease. Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide cardiovascular benefits, but their association with cardiovascular outcomes in patients with psoriasis remains insufficiently studied. METHODS: We conducted a retrospective cohort study using the global TriNetX research network. Patients older than 40 years with plaque psoriasis receiving biologic therapy were categorized according to SGLT2 inhibitor use. Propensity score matching was performed to balance demographic characteristics, cardiovascular risk factors, kidney disease, and concomitant antidiabetic medications. RESULTS: After matching, 2016 patients were included in each cohort. SGLT2 inhibitor use was associated with a significantly lower incidence of acute myocardial infarction (HR, 0.601; 95%CI, 0.426-0.849), stroke (HR, 0.553; 95%CI, 0.381-0.804), heart failure (HR, 0.751; 95%CI, 0.581-0.970), peripheral artery disease (HR, 0.648; 95%CI, 0.470-0.894), and angina pectoris (HR, 0.601; 95%CI, 0.404-0.894). No significant association was observed for transient ischemic attack. CONCLUSIONS: SGLT2 inhibitor use was associated with favorable cardiovascular outcomes in patients with moderate-to-severe psoriasis receiving biologic therapy. These findings support further prospective investigation of SGLT2 inhibitors as a potential strategy for cardiovascular risk reduction in this population.

Schlagwörter

Stichwörter der Autor:innen

Cardiovascular riskPsoriasisSGLT2 inhibitorTriNetX

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Universitario "12 de Octubre", Madrid, Spain. Electronic address: alfonso.gotor@salud.madrid.org.
  • Data Unit, Department of Information Technology, Hospital Universitario "12 de Octubre", Madrid, Spain.
  • Department of Dermatology, Hospital Universitario "12 de Octubre", Madrid, Spain.
  • Department of Dermatology, Hospital Universitario "12 de Octubre", Madrid, Spain; Oncology Research Group, Fundación imas12, Hospital Universitario "12 de Octubre", Madrid, Spain; Department of Medicine, Faculty of Medi…
  • Department of Dermatology, Hospital Universitario "12 de Octubre", Madrid, Spain; Department of Medicine, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain.

Zitieren

APA

Gotor-Rivera, A., Hernández Sánchez, J., Chamorro Jiménez, E., García Rivera, E., Ortiz Romero, P. L., & Rivera-Diaz, R. (2027). SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Moderate-to-Severe Psoriasis Receiving Biologic Therapy: A Propensity Score-Matched Cohort Study. Actas Dermo-Sifiliográficas, 118(2), 104756. https://doi.org/10.1016/j.ad.2026.104756

Vancouver

Gotor-Rivera A, Hernández Sánchez J, Chamorro Jiménez E, García Rivera E, Ortiz Romero PL, Rivera-Diaz R. SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Moderate-to-Severe Psoriasis Receiving Biologic Therapy: A Propensity Score-Matched Cohort Study. Actas Dermo-Sifiliográficas. 2027;118(2):104756. doi:10.1016/j.ad.2026.104756

BibTeX
@article{GotorRivera2027,
  author = {Gotor-Rivera, A and Hernández Sánchez, J and Chamorro Jiménez, E and García Rivera, E and Ortiz Romero, P L and Rivera-Diaz, R},
  title = {SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Moderate-to-Severe Psoriasis Receiving Biologic Therapy: A Propensity Score-Matched Cohort Study},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2027},
  volume = {118},
  number = {2},
  pages = {104756},
  doi = {10.1016/j.ad.2026.104756}
}
Kostenlos starten →